Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting
Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 7, 2022
by PharmaSources.com
Potential new CAR-T cell therapy for multiple myeloma
Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet.
June 28, 2021
by firstwordpharma
SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting
SOTIO today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting.
June 7, 2021
by b3cnewswire
Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annu
Shanghai Yingli Pharmaceuticals Ltd announced today that there will be three presentations on clinical trials sponsored by the company at the annual meeting of the American Society for Clinical Oncology (ASCO) June 4-7, 2021.
June 4, 2021
by prnasia
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021
ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8, 2021 for the first time.
June 3, 2021
by prnasia
Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting
Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held from June 4th to 8th.
June 2, 2021
by prnasia
Janssen’s Phase 1 Results for Teclistamab Suggest Deep, Durable Responses
Subcutaneous administration of BCMAxCD3 T-cell redirecting bispecific antibody demonstrated clinical activity and a manageable safety profile according to new data at ASCO.
May 28, 2021
by americanpharmaceuticalreview
HPV Vaccination Is Lowering U.S. Cervical Cancer Rates
In a finding that offers the first evidence that the human papillomavirus (HPV) vaccine is indeed protecting women from cervical cancer, new research shows cases in the United States have slowly but steadily declined over the last decade and a half.
May 20, 2021
by drugs
Clovis Oncology Highlights Rubraca (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting
Clovis Oncology, today announced that four abstracts featuring data will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually, June 4-8, 2021.
May 20, 2021
by firstwordpharma
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting
ImmVira announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8 2021.
April 9, 2021
by prnasia
COVID-19: AstraZeneca to distribute masks as ASCO goes virtual
As of this morning - Wednesday 25th March - the current recorded case count for COVID-19 (coronavirus) in the UK has hit 8,077, with 422 deaths and 135 recoveries.
March 26, 2020
by pharmatimes
MammaPrint® Becomes Only Molecular Diagnostic Recommended for Early-Stage Node-Positive Breast Cancer Patients in ASCO-Endorsed Cancer Care
MammaPrint® Becomes Only Molecular Diagnostic Recommended for Early-Stage Node-Positive Breast Cancer Patients in ASCO-Endorsed Cancer Care Ontario Guidelines.
June 27, 2019
by b3cnewswire